A61K 38/212
Ifn-alpha
Official title: {IFN-alpha}
A61K38/212 (Ifn-alpha) appears on 915 US grants and 1,594 published applications in this corpus.
Search patents in A61K- Granted patents
- 915
- Published applications
- 1,594
- Assignees
- 659
- Inventors
- 2,489
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 1 | 0 |
| 1988 | 4 | 0 |
| 1989 | 14 | 0 |
| 1990 | 1 | 0 |
| 1991 | 6 | 0 |
| 1992 | 5 | 0 |
| 1993 | 2 | 0 |
| 1994 | 4 | 0 |
| 1995 | 6 | 0 |
| 1996 | 6 | 0 |
| 1997 | 17 | 0 |
| 1998 | 25 | 0 |
| 1999 | 38 | 0 |
| 2000 | 20 | 0 |
| 2001 | 18 | 10 |
| 2002 | 29 | 46 |
| 2003 | 11 | 53 |
| 2004 | 14 | 47 |
| 2005 | 17 | 70 |
| 2006 | 10 | 62 |
| 2007 | 13 | 91 |
| 2008 | 17 | 62 |
| 2009 | 35 | 74 |
| 2010 | 24 | 49 |
| 2011 | 22 | 60 |
| 2012 | 34 | 57 |
| 2013 | 38 | 82 |
| 2014 | 47 | 122 |
| 2015 | 71 | 91 |
| 2016 | 60 | 95 |
| 2017 | 55 | 70 |
| 2018 | 43 | 60 |
| 2019 | 43 | 55 |
| 2020 | 33 | 58 |
| 2021 | 21 | 56 |
| 2022 | 20 | 73 |
| 2023 | 26 | 50 |
| 2024 | 29 | 43 |
| 2025 | 23 | 40 |
| 2026 | 8 | 18 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Application of PEG-interferon and protooncogene product targeting inhibitor in synergistic inhibition of tumors22 Sep 2026US 12,741,012 B2Shanghai Institute of Biological Products Co., Ltd.
- Use of membrane inhibitors to enhance vaccine development against enveloped viruses8 Sep 2026US 12,728,161 B2Cornell University
- Compositions and methods for cancer therapy25 Aug 2026US 12,714,723 B2AIM ImmunoTech Inc.
- Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 216 Jun 2026US 12,655,186 B2Orionis Biosciences BV
- Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases2 Jun 2026US 12,642,817 B2The Johns Hopkins University
- Methods of treating chronic hepatitis b24 Sep 2026US 2026/0286361 A1GlaxoSmithKline Intellectual Property Development Limited
- Synthekine Compositions and Methods of Use10 Sep 2026US 2026/0263562 A1The Board of Trustees of the Leland Stanford Junior University
- Dosing regime and formulations for type b adenoviruses30 Jul 2026US 2026/0216263 A1Akamis Bio Limited
- Methylene blue for use in therapy of hepatitis b and/or hepatitis d infection2 Jul 2026US 2026/0183305 A1
- In vivo production of proteins25 Jun 2026US 2026/0174909 A1ModernaTX, Inc.
Most cited
By later US patents
- Retrograde tissue splitter and method1,605US 5,449,355 AValleylab, Inc. · 1995
- Retrograde tissue splitter and method1,585US 5,797,906 AValleylab, Inc. · 1998
- Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1328US 7,595,048 B2Ono Pharmaceutical Co., Ltd. · 2009
- Modulated release from biocompatible polymers263US 5,656,297 AAlkermes Controlled Therapeutics, Inc. · 1997
- Immunopotentiative composition237US 8,728,474 B2Ono Pharmaceutical Co., Ltd. · 2014